(Q30419845)

16 August 2017

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research (English)

1 reference

16 August 2017

1 reference

10

Muin J Khoury

1 reference

16 August 2017

6

Sheri D Schully

1 reference

Heather Spencer Feigelson

16 August 2017

5

object named as

Heather Spencer Feigelson

1 reference

16 August 2017

11

David L Veenstra

1 reference

16 August 2017

7

Scott Ramsey

1 reference

16 August 2017

3

Evelyn Whitlock

1 reference

16 August 2017

8

Sean Tunis

1 reference

16 August 2017

Katrina A B Goddard

1

1 reference

16 August 2017

William A Knaus

2

1 reference

16 August 2017

Gary H Lyman

4

1 reference

16 August 2017

Andrew N Freedman

9

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 July 2012

1 reference

16 August 2017

1 reference

16 August 2017

14

1 reference

16 August 2017

7

1 reference

16 August 2017

633-642

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

16 August 2017

1 reference

Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A CTSA agenda to advance methods for comparative effectiveness research

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Horizon scanning for new genomic tests

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

The promise and realities of comparative effectiveness research

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Comparative effectiveness research: Policy context, methods development and research infrastructure

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

White paper on CTSA consortium role in facilitating comparative effectiveness research: September 23, 2009 CTSA consortium strategic goal committee on comparative effectiveness research

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Cost-effectiveness analysis in pharmacogenomics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Stakeholder perspectives on a risk-benefit framework for genetic testing

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Performance of common genetic variants in breast-cancer risk models

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Health spending projections through 2019: the recession's impact continues

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Access with evidence development: the US experience

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Coverage with Evidence Development: applications and issues

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Translational research in cancer genetics: the road less traveled

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Expectations, validity, and reality in pharmacogenetics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Realising the potential of the family history in risk assessment and primary prevention of coronary heart disease in primary care: ADDFAM study protocol

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Curses--winner's and otherwise--in genetic epidemiology

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Why Most Discovered True Associations Are Inflated

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Internal and external validity of cluster randomised trials: systematic review of recent trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Cluster randomized trials: opportunities and barriers identified by leaders of eight health plans

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Creating and synthesizing evidence with decision makers in mind: integrating evidence from clinical trials and other study designs

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

The GRAIDS Trial: a cluster randomised controlled trial of computer decision support for the management of familial cancer risk in primary care

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Replicating genotype-phenotype associations

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Developments in post-marketing comparative effectiveness research

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Using value of information analysis to prioritise health research: some lessons from recent UK experience

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A review of uses of health care utilization databases for epidemiologic research on therapeutics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Design and analysis of group-randomized trials: a review of recent practices

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Using routine comparative data to assess the quality of health care: understanding and avoiding common pitfalls

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3632438

The historical and moral imperatives of comparative effectiveness research.

20 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

Familial risk for common diseases in primary care: the Family Healthware Impact Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

What is the clinical utility of genetic testing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

Bayesian and classical estimation of mixed logit: An application to genetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

How best to engage patients, doctors, and other stakeholders in designing comparative effectiveness studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

Evaluating the utility of personal genomic information

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

On the limitations of comparative effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

Principles and indicators of successful consumer involvement in NHS research: results of a Delphi study and subgroup analysis

21 January 2018

1 reference

12 December 2020

Modeling comparative effectiveness and the value of research

1 reference

12 December 2020

The cross-validated adaptive signature design

1 reference

12 December 2020

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

12 December 2020

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

12 December 2020

When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?

1 reference

12 December 2020

Explanatory and pragmatic attitudes in therapeutical trials

1 reference

12 December 2020

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FGIM.2012.16

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/GIM.2012.16

1 reference

16 August 2017

1 reference

16 August 2017

1 reference